Information Provided By: 
Fly News Breaks for April 19, 2016
SNY, REGN
Apr 19, 2016 | 07:15 EDT
Jefferies analyst Biren Amin says his firm's survey of 50 cardiologists suggests trends for Sanofi (SNY) and Regeneron's (REGN) Praluent is tracking below expectations. The analyst believes the physician expectations are in-line with his, which are below consensus. His estimates translate to Praluent sales of $300M for 2016 and $666M for 2017, which he notes are well below consensus expectations of $445M for 2016 and $1.0B for 2017. Amin keeps a Hold rating on Regeneron with a $444 price target.
News For REGN;SNY From the Last 2 Days
